Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.
Open Access
- 1 April 1993
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 90 (7) , 2774-2778
- https://doi.org/10.1073/pnas.90.7.2774
Abstract
Interleukin (IL)-2, IL-4, IL-7, tumor necrosis factor (TNF), or interferon-gamma (IFN-gamma) has been shown to be able to induce tumor rejection if produced locally by the tumor cells after gene transfer. To analyze whether the cellular rejection mechanisms are different or redundant we have expressed the cytokines in the same tumor cell line (J558L). Cell depletion experiments revealed that all cytokines required CD8+ T cells for complete long-term tumor eradication, although effective but transient host-dependent tumor suppression was also observed in the complete absence of CD8+ T cells. The transient tumor suppression induced by IL-2, IL-4, TNF, or IFN-gamma was also operative in nude and severe combined immunodeficient mice, whereas only tumor suppression induced by IL-7 was dependent on the presence of CD4+ T cells and was not evident in nude mice. The T-cell-independent effector arm of IL-2 and IFN-gamma but not IL-4 and TNF was mediated in part by natural killer cells. The transience of tumor suppression in the absence of T cells reflected loss of cytokine production in the case of TNF, IL-2, and IL-4 but not IFN-gamma. Immunohistologic analysis revealed all cytokine-producing tumors to be heavily infiltrated by macrophages. IL-4 and IL-7 tumors additionally contained eosinophils. The infiltration by T cells did not necessarily reflect their contribution to tumor rejection. Thus, the different cytokines activate heterogeneous transient tumor-suppressive mechanisms but always require CD8+ T cells for complete tumor rejection.Keywords
This publication has 36 references indexed in Scilit:
- Macrophage colony‐stimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppressionEuropean Journal of Immunology, 1993
- An Eosinophil-Dependent Mechanism for the Antitumor Effect of Interleukin-4Science, 1992
- Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4Science, 1991
- Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4Molecular Immunology, 1990
- Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor responseCell, 1990
- Murine interleukin-4 displays potent anti-tumor activity in vivoCell, 1989
- Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies.The Journal of Experimental Medicine, 1987
- Tumors secreting human TNF/cachectin induce cachexia in miceCell, 1987
- Production of a monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1Nature, 1985
- F4/80, a monoclonal antibody directed specifically against the mouse macrophageEuropean Journal of Immunology, 1981